COVID-19 Convalescent Plasma Therapy: Long-term Implications

Author:

Yoon Hyunah1,Li Yi2,Goldfeld Keith S2,Cobb Gia F3,Sturm-Reganato Caroline L3,Ostrosky-Zeichner Luis4ORCID,Jayaweera Dushyantha T56,Philley Julie V7,Desruisseaux Mahalia S8,Keller Marla J19,Hochman Judith S10,Pirofski Liise-anne111ORCID,Ortigoza Mila B1213ORCID,Hochman Judith S,Cronstein Bruce N,Keeling Deborah,Rappoport Norka,Saraga Jenna,Holahan James,Ortigoza Mila B,Pirofski Liise-anne,Yoon Hyunah,Sturm-Reganato Caroline L,Cobb Gia F,Andela Rakshit,Darwish Yousef,Taveras Monica R,Xin Patrick S,LaFleur Jeff,Cleare Levi,Goldfeld Keith S,Li Yi,Ortigoza Mila B,O'Keeffe Mary L,Cobb Gia F,Sturm-Reganato Caroline L,Rahman Fatema Z,Ajayi Adeyinka O,Rodriguez Sara L,Iturrate Eduardo,Gallagher Jacqueline M,Thomas Ololade E,Ramos Danibel,Fong Charlotte C,Pirofski Liise-anne,Yoon Hyunah,Keller Marla J,Asencio Andrea A,Eke Isaiah,Castro James,Shan Jidong,Chalco Alex,LaFleur Jeff,Cleare Levi,Desruisseaux Mahalia,Cortezzo Grace M,Rocco Erica,Ndunge Oscar Bate Akide,Parmelee Catherine,Solomon Gina,Cahil Staci,Jayaweera Dushyantha T,Lee Chin Chin,Ransford Daru L,Dasmany Deniz,Corona Andres,Moreno Kenia,Martinez Gledys L,Otero Christopher,McPherson David D,Ostrosky-Zeichner Luis,Patel Bela,Nigo Masayuki,Huebinger Ryan M,Dronavalli Goutham,Grimes Carolyn Z,Umana Virginia E,Hernandez Maria D,Nielsen Laura E,Stutz Taylor P,Mammadova Mehriban,Dentino Andrew N,Heath Timothy R,Martin Jessica G,Bello Fatimah O,Hinojosa Erik,Philley Julie V,Devine Megan S,Hibbard Rebekah L,Ford Anne M,

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center , Bronx, New York , USA

2. Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine , New York, New York , USA

3. Department of Medicine, NYU Grossman School of Medicine , New York, New York , USA

4. Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School , Houston, Texas , USA

5. Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine , Miami, Florida , USA

6. Miami Clinical and Translational Science Institute, University of Miami Miller School of Medicine, Miami , Florida , USA

7. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Tyler, UTHealth East Texas , Tyler, Texas , USA

8. Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine , New Haven, Connecticut , USA

9. Harold and Muriel Block Institute for Clinical and Translational Research, Albert Einstein College of Medicine and Montefiore Medical Center , Bronx, New York , USA

10. Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine , New York, New York , USA

11. Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York , USA

12. Division of Infectious Diseases, Department of Medicine, NYU Grossman School of Medicine , New York, New York , USA

13. Department of Microbiology, NYU Grossman School of Medicine , New York, New York , USA

Abstract

Abstract Background The long-term effect of coronavirus disease 2019 (COVID-19) acute treatments on postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) is unknown. The CONTAIN-Extend study explores the long-term impact of COVID-19 convalescent plasma (CCP) therapy on postacute sequelae of SARS-CoV-2 infection (PASC) symptoms and general health 18 months following hospitalization. Methods The CONTAIN-Extend study examined 281 participants from the original CONTAIN COVID-19 trial (CONTAIN-RCT, NCT04364737) at 18 months post–hospitalization for acute COVID-19. Symptom surveys, global health assessments, and biospecimen collection were performed from November 2021 to October 2022. Multivariable logistic and linear regression estimated associations between the randomization arms and self-reported symptoms and Patient-Reported Outcomes Measurement Information System (PROMIS) scores and adjusted for covariables, including age, sex, race/ethnicity, disease severity, and CONTAIN enrollment quarter and sites. Results There were no differences in symptoms or PROMIS scores between CCP and placebo (adjusted odds ratio [aOR] of general symptoms, 0.95; 95% CI, 0.54–1.67). However, females (aOR, 3.01; 95% CI, 1.73–5.34), those 45–64 years (aOR, 2.55; 95% CI, 1.14–6.23), and April–June 2020 enrollees (aOR, 2.39; 95% CI, 1.10–5.19) were more likely to report general symptoms and have poorer PROMIS physical health scores than their respective reference groups. Hispanic participants (difference, −3.05; 95% CI, −5.82 to −0.27) and Black participants (−4.48; 95% CI, −7.94 to −1.02) had poorer PROMIS physical health than White participants. Conclusions CCP demonstrated no lasting effect on PASC symptoms or overall health in comparison to the placebo. This study underscores the significance of demographic factors, including sex, age, and timing of acute infection, in influencing symptom reporting 18 months after acute hypoxic COVID-19 hospitalization.

Funder

NCATS

NIH

New York University

Albert Einstein College of Medicine

Yale University

University of Miami

University of Texas Health Sciences Center Houston

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Reference52 articles.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3